TrialJournal of clinical immunology2017

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.

Michael Borte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.